Forest Laboratories makes significant company improvements as AstraZeneca considers possible buyout.
Repros wins meeting with FDA for oral testosterone frontrunner Androxal after FDA concerns last month tanked shares
Exelixis, Cell Therapeutics, Isis Pharmaceuticals, and Amarin could make health care headlines this morning. Here's why.
These five experimental therapies, if approved, could result in improved quality of life for millions of Americans in 2014.
Ariad Pharmaceuticals, AstraZeneca, and XOMA are three health care stocks poised to be on the move today.
Just because it's nearly December doesn't mean the FDA or pharmaceutical sector takes the month off. Make sure you circle these three critical dates on your calendar, as the FDA is about to make three important decisions you won't want to miss.
Johnson & Johnson beats Gilead Sciences to deliver the first next-generation hepatitis C drug approved in the U.S., but a battle with Vertex Pharmaceuticals' and Merck's first-generation drugs will be short lived with Gilead and AbbVie developing all-oral cocktails.
Amarin continues to suffer from data from trials of AbbVie's and Merck's drugs, unable to compete with GlaxoSmithKline until Vascepa's label is expanded.
Horizon Pharma, Amarin, and Tile Shop were among today's top performers. Find out how they were able to buck a modestly down day for the S&P 500.
Wall Street panicked at the end of 2000 when Abbott Labs announced it was acquiring the pharmaceutical business of BASF. Shares sank 7.1% the next trading day on fears of dilution and a lack of execution. Turns out that was a great buying opportunity.